Study Comparing Belantamab Mafodotin to Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Inclusion Criteria

• Able to provide informed consent.
• Aged 18 or older (19 in South Korea).
• Performance status score of 0 to 2, indicating full activity or some restriction in strenuous activities.
• Confirmed diagnosis of multiple myeloma, having undergone or being ineligible for stem cell transplant.
• Received at least two prior treatments for multiple myeloma, including lenalidomide and a proteasome inhibitor, with disease progression or non-response.
• Measurable disease with specific protein levels in blood or urine.
• If previously had a stem cell transplant, it must have been over 100 days ago with no active infections.
• Adequate organ function based on specific blood test results.
• Agree to use effective contraception during and after the study, with specific requirements for men and women depending on the treatment arm.
• All previous treatment-related side effects must be mild or resolved, except for hair loss and mild nerve damage.

Exclusion Criteria

• Active amyloidosis, POEMS syndrome, or plasma cell leukemia.
• Recent treatment with anti-myeloma drugs or investigational drugs.
• Previous treatment with certain monoclonal antibodies or specific therapies.
• Recent plasmapheresis or major surgery.
• Active kidney issues requiring dialysis or affecting safety.
• Serious medical or psychiatric conditions that could interfere with the study.
• History of lung inflammation requiring steroids.
• Active bleeding or unstable liver disease.
• Other cancers unless stable for at least two years.
• Significant heart issues or uncontrolled high blood pressure.
• Allergies to study drugs.
• Pregnant or breastfeeding women.
• Active infections requiring treatment.
• HIV or hepatitis infections unless controlled with specific criteria.
• Unable to tolerate blood clot prevention medications.
• Current eye conditions affecting the cornea.